MA39378B2 - Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer - Google Patents

Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer

Info

Publication number
MA39378B2
MA39378B2 MA39378A MA39378A MA39378B2 MA 39378 B2 MA39378 B2 MA 39378B2 MA 39378 A MA39378 A MA 39378A MA 39378 A MA39378 A MA 39378A MA 39378 B2 MA39378 B2 MA 39378B2
Authority
MA
Morocco
Prior art keywords
antibody
igf
treatment
relates
cancer
Prior art date
Application number
MA39378A
Other languages
English (en)
Other versions
MA39378A1 (fr
Inventor
Charlotte Beau-Larvor
Liliane Goetsch
Matthieu Broussas
Thierry Champion
Alain Robert
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MA39378A1 publication Critical patent/MA39378A1/fr
Publication of MA39378B2 publication Critical patent/MA39378B2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne un anticorps, en particulier un anticorps monoclonal, pouvant se lier spécifiquement à igf-1r, ainsi que des séquences d'acides aminés et d'acides nucléiques codant pour cet anticorps. Dans un aspect, l'invention concerne un anticorps, ou un fragment de liaison d'antigène de celui-ci, pouvant se lier à l'igf-1r et, par l'induction d'une internalisation d'igf-1r, étant internalisé dans la cellule. L'invention concerne également l'utilisation de cet anticorps en tant que véhicule d'adressage conjugué à d'autres composés anticancéreux, tels que des toxines, des radioéléments ou des médicaments, et l'utilisation de ceux-ci pour le traitement de certains cancers.
MA39378A 2014-04-25 2015-04-27 Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer MA39378B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461984160P 2014-04-25 2014-04-25
PCT/EP2015/059050 WO2015162292A1 (fr) 2014-04-25 2015-04-27 Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer

Publications (2)

Publication Number Publication Date
MA39378A1 MA39378A1 (fr) 2018-05-31
MA39378B2 true MA39378B2 (fr) 2021-02-26

Family

ID=53373391

Family Applications (2)

Application Number Title Priority Date Filing Date
MA53069A MA53069B1 (fr) 2014-04-25 2015-04-27 Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer
MA39378A MA39378B2 (fr) 2014-04-25 2015-04-27 Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA53069A MA53069B1 (fr) 2014-04-25 2015-04-27 Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer

Country Status (29)

Country Link
US (2) US10202458B2 (fr)
EP (2) EP3134438B1 (fr)
JP (2) JP6835591B2 (fr)
KR (3) KR102177436B1 (fr)
CN (2) CN112851808B (fr)
AU (1) AU2015250760C1 (fr)
BR (1) BR112016024575B1 (fr)
CA (1) CA2946795C (fr)
CY (1) CY1123743T1 (fr)
DK (1) DK3134438T3 (fr)
ES (1) ES2841249T3 (fr)
HR (1) HRP20202047T1 (fr)
HU (1) HUE052223T2 (fr)
IL (2) IL248357B (fr)
LT (1) LT3134438T (fr)
MA (2) MA53069B1 (fr)
MX (2) MX380358B (fr)
MY (1) MY182444A (fr)
NZ (1) NZ725423A (fr)
PL (1) PL3134438T3 (fr)
PT (1) PT3134438T (fr)
RS (1) RS61379B1 (fr)
RU (1) RU2698977C2 (fr)
SA (1) SA516380131B1 (fr)
SI (1) SI3134438T1 (fr)
TN (1) TN2016000445A1 (fr)
UA (1) UA122390C2 (fr)
WO (1) WO2015162292A1 (fr)
ZA (1) ZA201607095B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20190888T8 (hr) * 2014-04-25 2019-10-04 Pierre Fabre Médicament Konjugat antitijela za igf-1r i lijeka i njegova upotreba u liječenju karcinoma
KR20180105634A (ko) * 2015-10-26 2018-09-28 피에르 파브르 메디카먼트 Igf-1r을 발현하는 암의 치료를 위한 조성물
EP3565841A1 (fr) * 2017-01-06 2019-11-13 Crescendo Biologics Limited Anticorps à domaine unique dirigés contre pd1 (mort cellulaire programmée 1)
EP3710478A1 (fr) 2017-11-13 2020-09-23 Crescendo Biologics Limited Molécules se liant à cd137 et psma
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
CN112740043A (zh) 2018-07-20 2021-04-30 皮埃尔法布雷医药公司 Vista受体
EP3856258B1 (fr) 2018-09-27 2024-07-31 Pierre Fabre Medicament Lieurs à base de sulfomaléimide et conjugués correspondants
WO2020079229A1 (fr) * 2018-10-19 2020-04-23 Medimmune Limited Conjugués de pyrrolobenzodiazépine
US20220306736A1 (en) 2019-09-04 2022-09-29 Y-Biologics Inc. Anti-vsig4 antibody or antigen binding fragment and uses thereof
EP4353220A1 (fr) 2022-10-12 2024-04-17 Pierre Fabre Medicament Utilisation d'une composition aqueuse liquide pour la solubilisation et la stabilisation d'un conjugué anticorps-médicament
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (fr) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026015801A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble liés à ras
WO2026015796A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015790A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015825A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026050446A1 (fr) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026072904A2 (fr) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions et méthodes de traitement du cancer du poumon

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FR2661000B1 (fr) 1990-04-12 1992-08-07 Aerospatiale Machine d'essais d'eprouvettes en cisaillement.
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5561427A (en) 1994-12-30 1996-10-01 Psc Inc. Analog to digital converter with continuous conversion cycles and large input signal range
FR2873699B1 (fr) * 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
FR2888850B1 (fr) * 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
AU2007245164A1 (en) * 2006-03-28 2007-11-08 Biogen Idec Ma Inc. Anti-IGF-IR antibodies and uses thereof
AR064464A1 (es) * 2006-12-22 2009-04-01 Genentech Inc Anticuerpos anti - receptor del factor de crecimiento insulinico
CL2008001334A1 (es) 2007-05-08 2008-09-22 Genentech Inc Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
NZ584514A (en) 2007-10-19 2012-07-27 Genentech Inc Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
SI2528625T1 (sl) 2010-04-15 2013-11-29 Spirogen Sarl Pirolobenzodiazepini in njihovi konjugati
US8476409B2 (en) * 2011-04-19 2013-07-02 Merrimack Pharmaceuticals, Inc. Bispecific anti-IGF-1R and anti-ErbB3 antibodies

Also Published As

Publication number Publication date
KR20200128210A (ko) 2020-11-11
LT3134438T (lt) 2021-01-11
JP2017513898A (ja) 2017-06-01
EP3134438B1 (fr) 2020-09-30
CN112851808B (zh) 2024-12-06
KR102357032B1 (ko) 2022-02-08
US20170267766A1 (en) 2017-09-21
RU2016145277A3 (fr) 2018-12-13
JP2021073279A (ja) 2021-05-13
IL274226A (en) 2020-06-30
BR112016024575A2 (pt) 2017-10-10
HUE052223T2 (hu) 2021-04-28
DK3134438T3 (da) 2020-12-07
TN2016000445A1 (en) 2018-04-04
MX2021002144A (es) 2021-03-09
PL3134438T3 (pl) 2021-04-06
ZA201607095B (en) 2020-07-29
IL248357B (en) 2020-05-31
MA53069A1 (fr) 2021-10-29
US10202458B2 (en) 2019-02-12
EP3783033A1 (fr) 2021-02-24
MY182444A (en) 2021-01-25
ES2841249T3 (es) 2021-07-07
MA39378A1 (fr) 2018-05-31
KR20220018620A (ko) 2022-02-15
AU2015250760A1 (en) 2016-11-03
CY1123743T1 (el) 2022-03-24
CN106459204B (zh) 2021-02-02
MX2016014000A (es) 2017-05-30
US20190330353A1 (en) 2019-10-31
EP3134438A1 (fr) 2017-03-01
PT3134438T (pt) 2020-12-31
JP6835591B2 (ja) 2021-02-24
SA516380131B1 (ar) 2019-12-04
JP7191134B2 (ja) 2022-12-16
CA2946795A1 (fr) 2015-10-29
WO2015162292A1 (fr) 2015-10-29
SI3134438T1 (sl) 2021-04-30
RU2016145277A (ru) 2018-05-28
MA53069B1 (fr) 2022-04-29
CN112851808A (zh) 2021-05-28
AU2015250760B2 (en) 2020-10-22
UA122390C2 (uk) 2020-11-10
US11365259B2 (en) 2022-06-21
HRP20202047T1 (hr) 2021-02-19
CN106459204A (zh) 2017-02-22
KR102177436B1 (ko) 2020-11-12
IL248357A0 (en) 2016-11-30
BR112016024575B1 (pt) 2024-02-27
RU2698977C2 (ru) 2019-09-02
RS61379B1 (sr) 2021-02-26
KR20160145110A (ko) 2016-12-19
CA2946795C (fr) 2021-03-30
AU2015250760C1 (en) 2023-11-16
MX380358B (es) 2025-03-12
NZ725423A (en) 2023-07-28

Similar Documents

Publication Publication Date Title
MA39378B2 (fr) Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer
MA35659B1 (fr) Protéine de liaison à un antigène et son utilisation comme produit d'adressage pour le traitement du cancer
MA40476A (fr) Anticorps et fragments de fixation à l'antigène anti-lag3
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
JOP20190187A1 (ar) مترافقات عقار جسم مضاد لـ ccr7
MA39909B1 (fr) Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer
MA49599B1 (fr) Anticorps spécifiques à cd47 et pd-l1
MA47313A (fr) Formulations sous-cutanées d'anticorps her2
PH12019500270A1 (en) Combination therapy for cancer
MX2024007724A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado
GEAP202214922A (en) Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof
MA45029B1 (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
BR112017025080A2 (pt) composto conjugado de fármaco com anticorpo anti-cd123, composição conjugada de fármaco com anticorpo, método de tratamento de um paciente que tem um câncer que expressa cd123, composição farmacêutica, e, anticorpo intacto ou fragmento de ligação de antígeno
MA40913A (fr) Conjugués anticorps-médicament
MA38194A1 (fr) Anticorps anti-ceacam5 et leurs utilisations
MD20170022A2 (ro) Anticorp monoclonal anti-CTLA4 sau fragment de legare a acestuia la antigen, compoziţie farmaceutică şi utilizarea lor
MA40513A (fr) Conjugués médicament-anticorps anti-cdh6
UA114891C2 (uk) ІЗОЛЬОВАНЕ АНТИТІЛО ЛЮДИНИ, ЯКЕ СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З АНГІОПОЕТИНПОДІБНИМ БІЛКОМ 3 ЛЮДИНИ (hАNGPTL3), ТА ЙОГО ЗАСТОСУВАННЯ
EP3906945A3 (fr) Acides nucléiques codant des anticorps humains contre le sialyl-lewis a
BR112019023909A8 (pt) Uso de um imunoconjugado que se liga a folr1, e, uso de um imunoconjugado que se liga a folr1 e pembrolizumab
MA33470B1 (fr) Polythérapie à base d'un anticorps afucosylé anti-cd20 et de fludarabine et/ou mitoxantrone
MA38161A1 (fr) Anticorps anti-bmp-6
EA201992318A1 (ru) Композиции и способы для диагностики и лечения рака предстательной железы с использованием молекулы, связывающей прогастрин
MA37961A1 (fr) Nouveaux traitements thérapeutiques par anticorps anti-her2 à basse fucosylation
WO2015191590A3 (fr) Polythérapies ciblant des stromas associés à une tumeur ou des cellules tumorales et des microtubules